World Federation of Hemophilia
-
WFH welcomes Bayer to Humanitarian Aid Program
The WFH Humanitarian Aid Program aims to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries,...
-
Now available: WFH Humanitarian Aid Program Impact Report 2018
A new report—called the “WFH Humanitarian Aid Program: Impact Report 2018”—has just been released. The document shows the impact that the WFH Humanitarian Aid Program...
-
Recommendation on the use of Cryoprecipitate
The Medical Advisory Board of the WFH has published recommendation on the use of Cryoprecipitate for Treatment of Congenital Bleeding Disorders, on 26 April 2019. The recommendations are as follows:...
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
-
CSL Behring today renews commitment to WFH
CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with the WFH for another three years. This is...
-
Happy new year from the WFH
The World Federation of Hemophilia (WFH) wishes you, your friends, your family, and the whole global bleeding disorders community a wonderful new year. Happy 2019!
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Glenn Pierce: a short bio of the new WFH Vice President, Medical
Glenn Pierce – WFH Vice President, Medical, WFH USA Board Member and Vice President Glenn Pierce, was elected to a four-year term as World Federation...
-
Glenn Pierce, VP Medical, discusses goals and challenges
Glenn Pierce, MD, PhD was elected as VP Medical for the World Federation of Hemophilia (WFH) at the WFH 2018 World Congress this past May...
